Global Arthritis Therapeutics Market

Arthritis Therapeutics Comprehensive Study by Application (Hospital and Healthcare, Pharmaceutical Industry), Route of Administration (Oral, Parenteral, Topical), Sales Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Drug Class (TNF Inhibitors, Interleukin Inhibitors, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Xanthine Oxidase Inhibitors, Others), Arthritis Type (Degenerative Arthritis (Osteoarthritis), Inflammatory Arthritis (Rheumatoid Arthritis), Infectious Arthritis, Metabolic Arthritis) Players and Region - Global Market Outlook to 2028

Arthritis Therapeutics Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Arthritis Therapeutics?
Arthritis Therapeutics is used to treat the inflammation of the joints. Arthritis can affect t can affect one joint or multiple joints. People of all ages, sex, and races can and do have arthritis, and it is the leading cause of disability in America. Joint pain, stiffness, and swelling are the most common symptoms of arthritis. As per sources, over 50 million adults and 300,000 children have some type of arthritis. It is most common among women and occurs more frequently in persons aging above 65 years. Globally, the annual incidence of rheumatoid arthritis is ~3 cases per 10,000 population and the prevalence rate is ~1%, increasing with age and peaking between the ages of 35 and 50 years. The rising cases of rheumatoid arthritis and osteoarthritis will drive the market growth throughout the forecast period.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledNovartis AG (Switzerland), Eli Lilly and Company (United States), Amgen Inc. (United States), Merck & Co., Inc. (United States), Bristol-Myers Squibb Company (United States), Pfizer Inc. (United States), Johnson & Johnson (United States), F. Hoffmann-La Roche Ltd (Switzerland), Bayer AG (Germany) and Sanofi S.A. (France)


The study covers a detailed analysis segmented by key business segments i.e. , by application (Hospital and Healthcare and Pharmaceutical Industry) and major geographies. Research Analyst at AMA predicts that United States and European Players will contribute to the maximum growth of Global Arthritis Therapeutics market throughout the predicted period.

The competition is expected to become even more intense in the years to come due to the entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this Arthritis Therapeutics market report suggests strategies that Players can follow and highlights key areas they should focus on, in order to take maximum benefits of growth opportunities.

The report offers several leading Players, some of them are Novartis AG (Switzerland), Eli Lilly and Company (United States), Amgen Inc. (United States), Merck & Co., Inc. (United States), Bristol-Myers Squibb Company (United States), Pfizer Inc. (United States), Johnson & Johnson (United States), F. Hoffmann-La Roche Ltd (Switzerland), Bayer AG (Germany) and Sanofi S.A. (France).

Market Overview:
In December 2021, Novartis global pharmaceutical manufacturer received approval from US Food and Drug Administration (FDA) for Cosentyx to treat active enthesitis-related arthritis (ERA) in four years and older, and active juvenile psoriatic arthritis (JPsA) in patients two years and older. This approval helped company to expand its presence in arthritis therapeutics market

The global arthritis therapeutics market is highly competitive and consists of a limited number of vendors who compete with each other. The intense competition, changing consumer spending patterns, and demographic trends pose significant risk factors for manufacturer’s growth.

Influencing Trend:
Self-Awareness And Pro-Activeness To Seek Treatment

Market Growth Drivers:
Increasing prevalence in geriatric population especially women and Growing Use of Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Challenges:
Growing Demand For Low-Priced Generics

Restraints:
High Cost Of Arthritis Drugs

Opportunities:
Increasing Obese Population Around The Globe and Rising Awareness About The Therapeutics In Emerging Economies

Key highlights of the Global Arthritis Therapeutics market Study:
• CAGR of the market during the forecast period 2022-2028
• In-depth information on growth factors that will accelerate the Arthritis Therapeutics market in next few years.
• Detailed Insights on futuristic trends and changing consumer behavior
• Forecast of the Global Arthritis Therapeutics market size and its contribution to the parent market by type, application and by country.
• A broad view of customer demand
• Uncover market’s competitive landscape and in-depth information on various Players
• Comprehensive information about factors that will challenge the growth of Arthritis Therapeutics Players

Transformation and Important Triggers:
Business transformation has taken hold across the broad corporate landscape due to the confluence of several important triggers, including:
• A tipping point in globalization
• A major slowdown in Western economies
• Significant shifts in technology and cost structure
• The challenges of regulatory compliance
• New forms of competition developing

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Arthritis Therapeutics market.
In order to reach an exhaustive list of functional and relevant players, various industry classification standards are closely followed such as NAICS, ICB, and SIC to penetrate deep into important geographies by players, and a thorough validation test is conducted to reach the most relevant players for survey in Arthritis Therapeutics market.
In order to make a priority list sorting is done based on revenue generated based on the latest reporting, using paid databases such as Factiva, Bloomberg, etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment> by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Arthritis Therapeutics Providers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists, Private Equity Firms, Government Regulatory and Research Organizations and End-User Industry.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth, etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that include Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases, etc.

Report Objectives / Segmentation Covered

By Application
  • Hospital and Healthcare
  • Pharmaceutical Industry
By Route of Administration
  • Oral
  • Parenteral
  • Topical

By Sales Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Drug Class
  • TNF Inhibitors
  • Interleukin Inhibitors
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Xanthine Oxidase Inhibitors
  • Others

By Arthritis Type
  • Degenerative Arthritis (Osteoarthritis)
  • Inflammatory Arthritis (Rheumatoid Arthritis)
  • Infectious Arthritis
  • Metabolic Arthritis

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing prevalence in geriatric population especially women
      • 3.2.2. Growing Use of Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
    • 3.3. Market Challenges
      • 3.3.1. Growing Demand For Low-Priced Generics
    • 3.4. Market Trends
      • 3.4.1. Self-Awareness And Pro-Activeness To Seek Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Arthritis Therapeutics, by Application, Route of Administration, Sales Channel, Drug Class, Arthritis Type and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Arthritis Therapeutics (Value)
      • 5.2.1. Global Arthritis Therapeutics by: Application (Value)
        • 5.2.1.1. Hospital and Healthcare
        • 5.2.1.2. Pharmaceutical Industry
      • 5.2.2. Global Arthritis Therapeutics by: Route of Administration (Value)
        • 5.2.2.1. Oral
        • 5.2.2.2. Parenteral
        • 5.2.2.3. Topical
      • 5.2.3. Global Arthritis Therapeutics by: Sales Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Online Pharmacies
      • 5.2.4. Global Arthritis Therapeutics by: Drug Class (Value)
        • 5.2.4.1. TNF Inhibitors
        • 5.2.4.2. Interleukin Inhibitors
        • 5.2.4.3. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
        • 5.2.4.4. Corticosteroids
        • 5.2.4.5. Xanthine Oxidase Inhibitors
        • 5.2.4.6. Others
      • 5.2.5. Global Arthritis Therapeutics by: Arthritis Type (Value)
        • 5.2.5.1. Degenerative Arthritis (Osteoarthritis)
        • 5.2.5.2. Inflammatory Arthritis (Rheumatoid Arthritis)
        • 5.2.5.3. Infectious Arthritis
        • 5.2.5.4. Metabolic Arthritis
      • 5.2.6. Global Arthritis Therapeutics Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Arthritis Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Eli Lilly and Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Amgen Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck & Co., Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bristol-Myers Squibb Company (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Johnson & Johnson (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bayer AG (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sanofi S.A. (France)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Arthritis Therapeutics Sale, by Application, Route of Administration, Sales Channel, Drug Class, Arthritis Type and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Arthritis Therapeutics (Value)
      • 7.2.1. Global Arthritis Therapeutics by: Application (Value)
        • 7.2.1.1. Hospital and Healthcare
        • 7.2.1.2. Pharmaceutical Industry
      • 7.2.2. Global Arthritis Therapeutics by: Route of Administration (Value)
        • 7.2.2.1. Oral
        • 7.2.2.2. Parenteral
        • 7.2.2.3. Topical
      • 7.2.3. Global Arthritis Therapeutics by: Sales Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Online Pharmacies
      • 7.2.4. Global Arthritis Therapeutics by: Drug Class (Value)
        • 7.2.4.1. TNF Inhibitors
        • 7.2.4.2. Interleukin Inhibitors
        • 7.2.4.3. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
        • 7.2.4.4. Corticosteroids
        • 7.2.4.5. Xanthine Oxidase Inhibitors
        • 7.2.4.6. Others
      • 7.2.5. Global Arthritis Therapeutics by: Arthritis Type (Value)
        • 7.2.5.1. Degenerative Arthritis (Osteoarthritis)
        • 7.2.5.2. Inflammatory Arthritis (Rheumatoid Arthritis)
        • 7.2.5.3. Infectious Arthritis
        • 7.2.5.4. Metabolic Arthritis
      • 7.2.6. Global Arthritis Therapeutics Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Arthritis Therapeutics: by Application(USD Million)
  • Table 2. Arthritis Therapeutics Hospital and Healthcare , by Region USD Million (2017-2022)
  • Table 3. Arthritis Therapeutics Pharmaceutical Industry , by Region USD Million (2017-2022)
  • Table 4. Arthritis Therapeutics: by Route of Administration(USD Million)
  • Table 5. Arthritis Therapeutics Oral , by Region USD Million (2017-2022)
  • Table 6. Arthritis Therapeutics Parenteral , by Region USD Million (2017-2022)
  • Table 7. Arthritis Therapeutics Topical , by Region USD Million (2017-2022)
  • Table 8. Arthritis Therapeutics: by Sales Channel(USD Million)
  • Table 9. Arthritis Therapeutics Hospital Pharmacies , by Region USD Million (2017-2022)
  • Table 10. Arthritis Therapeutics Retail Pharmacies , by Region USD Million (2017-2022)
  • Table 11. Arthritis Therapeutics Online Pharmacies , by Region USD Million (2017-2022)
  • Table 12. Arthritis Therapeutics: by Drug Class(USD Million)
  • Table 13. Arthritis Therapeutics TNF Inhibitors , by Region USD Million (2017-2022)
  • Table 14. Arthritis Therapeutics Interleukin Inhibitors , by Region USD Million (2017-2022)
  • Table 15. Arthritis Therapeutics Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) , by Region USD Million (2017-2022)
  • Table 16. Arthritis Therapeutics Corticosteroids , by Region USD Million (2017-2022)
  • Table 17. Arthritis Therapeutics Xanthine Oxidase Inhibitors , by Region USD Million (2017-2022)
  • Table 18. Arthritis Therapeutics Others , by Region USD Million (2017-2022)
  • Table 19. Arthritis Therapeutics: by Arthritis Type(USD Million)
  • Table 20. Arthritis Therapeutics Degenerative Arthritis (Osteoarthritis) , by Region USD Million (2017-2022)
  • Table 21. Arthritis Therapeutics Inflammatory Arthritis (Rheumatoid Arthritis) , by Region USD Million (2017-2022)
  • Table 22. Arthritis Therapeutics Infectious Arthritis , by Region USD Million (2017-2022)
  • Table 23. Arthritis Therapeutics Metabolic Arthritis , by Region USD Million (2017-2022)
  • Table 24. South America Arthritis Therapeutics, by Country USD Million (2017-2022)
  • Table 25. South America Arthritis Therapeutics, by Application USD Million (2017-2022)
  • Table 26. South America Arthritis Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 27. South America Arthritis Therapeutics, by Sales Channel USD Million (2017-2022)
  • Table 28. South America Arthritis Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 29. South America Arthritis Therapeutics, by Arthritis Type USD Million (2017-2022)
  • Table 30. Brazil Arthritis Therapeutics, by Application USD Million (2017-2022)
  • Table 31. Brazil Arthritis Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 32. Brazil Arthritis Therapeutics, by Sales Channel USD Million (2017-2022)
  • Table 33. Brazil Arthritis Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 34. Brazil Arthritis Therapeutics, by Arthritis Type USD Million (2017-2022)
  • Table 35. Argentina Arthritis Therapeutics, by Application USD Million (2017-2022)
  • Table 36. Argentina Arthritis Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 37. Argentina Arthritis Therapeutics, by Sales Channel USD Million (2017-2022)
  • Table 38. Argentina Arthritis Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 39. Argentina Arthritis Therapeutics, by Arthritis Type USD Million (2017-2022)
  • Table 40. Rest of South America Arthritis Therapeutics, by Application USD Million (2017-2022)
  • Table 41. Rest of South America Arthritis Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 42. Rest of South America Arthritis Therapeutics, by Sales Channel USD Million (2017-2022)
  • Table 43. Rest of South America Arthritis Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 44. Rest of South America Arthritis Therapeutics, by Arthritis Type USD Million (2017-2022)
  • Table 45. Asia Pacific Arthritis Therapeutics, by Country USD Million (2017-2022)
  • Table 46. Asia Pacific Arthritis Therapeutics, by Application USD Million (2017-2022)
  • Table 47. Asia Pacific Arthritis Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 48. Asia Pacific Arthritis Therapeutics, by Sales Channel USD Million (2017-2022)
  • Table 49. Asia Pacific Arthritis Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 50. Asia Pacific Arthritis Therapeutics, by Arthritis Type USD Million (2017-2022)
  • Table 51. China Arthritis Therapeutics, by Application USD Million (2017-2022)
  • Table 52. China Arthritis Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 53. China Arthritis Therapeutics, by Sales Channel USD Million (2017-2022)
  • Table 54. China Arthritis Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 55. China Arthritis Therapeutics, by Arthritis Type USD Million (2017-2022)
  • Table 56. Japan Arthritis Therapeutics, by Application USD Million (2017-2022)
  • Table 57. Japan Arthritis Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 58. Japan Arthritis Therapeutics, by Sales Channel USD Million (2017-2022)
  • Table 59. Japan Arthritis Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 60. Japan Arthritis Therapeutics, by Arthritis Type USD Million (2017-2022)
  • Table 61. India Arthritis Therapeutics, by Application USD Million (2017-2022)
  • Table 62. India Arthritis Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 63. India Arthritis Therapeutics, by Sales Channel USD Million (2017-2022)
  • Table 64. India Arthritis Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 65. India Arthritis Therapeutics, by Arthritis Type USD Million (2017-2022)
  • Table 66. South Korea Arthritis Therapeutics, by Application USD Million (2017-2022)
  • Table 67. South Korea Arthritis Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 68. South Korea Arthritis Therapeutics, by Sales Channel USD Million (2017-2022)
  • Table 69. South Korea Arthritis Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 70. South Korea Arthritis Therapeutics, by Arthritis Type USD Million (2017-2022)
  • Table 71. Taiwan Arthritis Therapeutics, by Application USD Million (2017-2022)
  • Table 72. Taiwan Arthritis Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 73. Taiwan Arthritis Therapeutics, by Sales Channel USD Million (2017-2022)
  • Table 74. Taiwan Arthritis Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 75. Taiwan Arthritis Therapeutics, by Arthritis Type USD Million (2017-2022)
  • Table 76. Australia Arthritis Therapeutics, by Application USD Million (2017-2022)
  • Table 77. Australia Arthritis Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 78. Australia Arthritis Therapeutics, by Sales Channel USD Million (2017-2022)
  • Table 79. Australia Arthritis Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 80. Australia Arthritis Therapeutics, by Arthritis Type USD Million (2017-2022)
  • Table 81. Rest of Asia-Pacific Arthritis Therapeutics, by Application USD Million (2017-2022)
  • Table 82. Rest of Asia-Pacific Arthritis Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 83. Rest of Asia-Pacific Arthritis Therapeutics, by Sales Channel USD Million (2017-2022)
  • Table 84. Rest of Asia-Pacific Arthritis Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 85. Rest of Asia-Pacific Arthritis Therapeutics, by Arthritis Type USD Million (2017-2022)
  • Table 86. Europe Arthritis Therapeutics, by Country USD Million (2017-2022)
  • Table 87. Europe Arthritis Therapeutics, by Application USD Million (2017-2022)
  • Table 88. Europe Arthritis Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 89. Europe Arthritis Therapeutics, by Sales Channel USD Million (2017-2022)
  • Table 90. Europe Arthritis Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 91. Europe Arthritis Therapeutics, by Arthritis Type USD Million (2017-2022)
  • Table 92. Germany Arthritis Therapeutics, by Application USD Million (2017-2022)
  • Table 93. Germany Arthritis Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 94. Germany Arthritis Therapeutics, by Sales Channel USD Million (2017-2022)
  • Table 95. Germany Arthritis Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 96. Germany Arthritis Therapeutics, by Arthritis Type USD Million (2017-2022)
  • Table 97. France Arthritis Therapeutics, by Application USD Million (2017-2022)
  • Table 98. France Arthritis Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 99. France Arthritis Therapeutics, by Sales Channel USD Million (2017-2022)
  • Table 100. France Arthritis Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 101. France Arthritis Therapeutics, by Arthritis Type USD Million (2017-2022)
  • Table 102. Italy Arthritis Therapeutics, by Application USD Million (2017-2022)
  • Table 103. Italy Arthritis Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 104. Italy Arthritis Therapeutics, by Sales Channel USD Million (2017-2022)
  • Table 105. Italy Arthritis Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 106. Italy Arthritis Therapeutics, by Arthritis Type USD Million (2017-2022)
  • Table 107. United Kingdom Arthritis Therapeutics, by Application USD Million (2017-2022)
  • Table 108. United Kingdom Arthritis Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 109. United Kingdom Arthritis Therapeutics, by Sales Channel USD Million (2017-2022)
  • Table 110. United Kingdom Arthritis Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 111. United Kingdom Arthritis Therapeutics, by Arthritis Type USD Million (2017-2022)
  • Table 112. Netherlands Arthritis Therapeutics, by Application USD Million (2017-2022)
  • Table 113. Netherlands Arthritis Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 114. Netherlands Arthritis Therapeutics, by Sales Channel USD Million (2017-2022)
  • Table 115. Netherlands Arthritis Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 116. Netherlands Arthritis Therapeutics, by Arthritis Type USD Million (2017-2022)
  • Table 117. Rest of Europe Arthritis Therapeutics, by Application USD Million (2017-2022)
  • Table 118. Rest of Europe Arthritis Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 119. Rest of Europe Arthritis Therapeutics, by Sales Channel USD Million (2017-2022)
  • Table 120. Rest of Europe Arthritis Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 121. Rest of Europe Arthritis Therapeutics, by Arthritis Type USD Million (2017-2022)
  • Table 122. MEA Arthritis Therapeutics, by Country USD Million (2017-2022)
  • Table 123. MEA Arthritis Therapeutics, by Application USD Million (2017-2022)
  • Table 124. MEA Arthritis Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 125. MEA Arthritis Therapeutics, by Sales Channel USD Million (2017-2022)
  • Table 126. MEA Arthritis Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 127. MEA Arthritis Therapeutics, by Arthritis Type USD Million (2017-2022)
  • Table 128. Middle East Arthritis Therapeutics, by Application USD Million (2017-2022)
  • Table 129. Middle East Arthritis Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 130. Middle East Arthritis Therapeutics, by Sales Channel USD Million (2017-2022)
  • Table 131. Middle East Arthritis Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 132. Middle East Arthritis Therapeutics, by Arthritis Type USD Million (2017-2022)
  • Table 133. Africa Arthritis Therapeutics, by Application USD Million (2017-2022)
  • Table 134. Africa Arthritis Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 135. Africa Arthritis Therapeutics, by Sales Channel USD Million (2017-2022)
  • Table 136. Africa Arthritis Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 137. Africa Arthritis Therapeutics, by Arthritis Type USD Million (2017-2022)
  • Table 138. North America Arthritis Therapeutics, by Country USD Million (2017-2022)
  • Table 139. North America Arthritis Therapeutics, by Application USD Million (2017-2022)
  • Table 140. North America Arthritis Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 141. North America Arthritis Therapeutics, by Sales Channel USD Million (2017-2022)
  • Table 142. North America Arthritis Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 143. North America Arthritis Therapeutics, by Arthritis Type USD Million (2017-2022)
  • Table 144. United States Arthritis Therapeutics, by Application USD Million (2017-2022)
  • Table 145. United States Arthritis Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 146. United States Arthritis Therapeutics, by Sales Channel USD Million (2017-2022)
  • Table 147. United States Arthritis Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 148. United States Arthritis Therapeutics, by Arthritis Type USD Million (2017-2022)
  • Table 149. Canada Arthritis Therapeutics, by Application USD Million (2017-2022)
  • Table 150. Canada Arthritis Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 151. Canada Arthritis Therapeutics, by Sales Channel USD Million (2017-2022)
  • Table 152. Canada Arthritis Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 153. Canada Arthritis Therapeutics, by Arthritis Type USD Million (2017-2022)
  • Table 154. Mexico Arthritis Therapeutics, by Application USD Million (2017-2022)
  • Table 155. Mexico Arthritis Therapeutics, by Route of Administration USD Million (2017-2022)
  • Table 156. Mexico Arthritis Therapeutics, by Sales Channel USD Million (2017-2022)
  • Table 157. Mexico Arthritis Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 158. Mexico Arthritis Therapeutics, by Arthritis Type USD Million (2017-2022)
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Arthritis Therapeutics: by Application(USD Million)
  • Table 170. Arthritis Therapeutics Hospital and Healthcare , by Region USD Million (2023-2028)
  • Table 171. Arthritis Therapeutics Pharmaceutical Industry , by Region USD Million (2023-2028)
  • Table 172. Arthritis Therapeutics: by Route of Administration(USD Million)
  • Table 173. Arthritis Therapeutics Oral , by Region USD Million (2023-2028)
  • Table 174. Arthritis Therapeutics Parenteral , by Region USD Million (2023-2028)
  • Table 175. Arthritis Therapeutics Topical , by Region USD Million (2023-2028)
  • Table 176. Arthritis Therapeutics: by Sales Channel(USD Million)
  • Table 177. Arthritis Therapeutics Hospital Pharmacies , by Region USD Million (2023-2028)
  • Table 178. Arthritis Therapeutics Retail Pharmacies , by Region USD Million (2023-2028)
  • Table 179. Arthritis Therapeutics Online Pharmacies , by Region USD Million (2023-2028)
  • Table 180. Arthritis Therapeutics: by Drug Class(USD Million)
  • Table 181. Arthritis Therapeutics TNF Inhibitors , by Region USD Million (2023-2028)
  • Table 182. Arthritis Therapeutics Interleukin Inhibitors , by Region USD Million (2023-2028)
  • Table 183. Arthritis Therapeutics Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) , by Region USD Million (2023-2028)
  • Table 184. Arthritis Therapeutics Corticosteroids , by Region USD Million (2023-2028)
  • Table 185. Arthritis Therapeutics Xanthine Oxidase Inhibitors , by Region USD Million (2023-2028)
  • Table 186. Arthritis Therapeutics Others , by Region USD Million (2023-2028)
  • Table 187. Arthritis Therapeutics: by Arthritis Type(USD Million)
  • Table 188. Arthritis Therapeutics Degenerative Arthritis (Osteoarthritis) , by Region USD Million (2023-2028)
  • Table 189. Arthritis Therapeutics Inflammatory Arthritis (Rheumatoid Arthritis) , by Region USD Million (2023-2028)
  • Table 190. Arthritis Therapeutics Infectious Arthritis , by Region USD Million (2023-2028)
  • Table 191. Arthritis Therapeutics Metabolic Arthritis , by Region USD Million (2023-2028)
  • Table 192. South America Arthritis Therapeutics, by Country USD Million (2023-2028)
  • Table 193. South America Arthritis Therapeutics, by Application USD Million (2023-2028)
  • Table 194. South America Arthritis Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 195. South America Arthritis Therapeutics, by Sales Channel USD Million (2023-2028)
  • Table 196. South America Arthritis Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 197. South America Arthritis Therapeutics, by Arthritis Type USD Million (2023-2028)
  • Table 198. Brazil Arthritis Therapeutics, by Application USD Million (2023-2028)
  • Table 199. Brazil Arthritis Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 200. Brazil Arthritis Therapeutics, by Sales Channel USD Million (2023-2028)
  • Table 201. Brazil Arthritis Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 202. Brazil Arthritis Therapeutics, by Arthritis Type USD Million (2023-2028)
  • Table 203. Argentina Arthritis Therapeutics, by Application USD Million (2023-2028)
  • Table 204. Argentina Arthritis Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 205. Argentina Arthritis Therapeutics, by Sales Channel USD Million (2023-2028)
  • Table 206. Argentina Arthritis Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 207. Argentina Arthritis Therapeutics, by Arthritis Type USD Million (2023-2028)
  • Table 208. Rest of South America Arthritis Therapeutics, by Application USD Million (2023-2028)
  • Table 209. Rest of South America Arthritis Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 210. Rest of South America Arthritis Therapeutics, by Sales Channel USD Million (2023-2028)
  • Table 211. Rest of South America Arthritis Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 212. Rest of South America Arthritis Therapeutics, by Arthritis Type USD Million (2023-2028)
  • Table 213. Asia Pacific Arthritis Therapeutics, by Country USD Million (2023-2028)
  • Table 214. Asia Pacific Arthritis Therapeutics, by Application USD Million (2023-2028)
  • Table 215. Asia Pacific Arthritis Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 216. Asia Pacific Arthritis Therapeutics, by Sales Channel USD Million (2023-2028)
  • Table 217. Asia Pacific Arthritis Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 218. Asia Pacific Arthritis Therapeutics, by Arthritis Type USD Million (2023-2028)
  • Table 219. China Arthritis Therapeutics, by Application USD Million (2023-2028)
  • Table 220. China Arthritis Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 221. China Arthritis Therapeutics, by Sales Channel USD Million (2023-2028)
  • Table 222. China Arthritis Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 223. China Arthritis Therapeutics, by Arthritis Type USD Million (2023-2028)
  • Table 224. Japan Arthritis Therapeutics, by Application USD Million (2023-2028)
  • Table 225. Japan Arthritis Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 226. Japan Arthritis Therapeutics, by Sales Channel USD Million (2023-2028)
  • Table 227. Japan Arthritis Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 228. Japan Arthritis Therapeutics, by Arthritis Type USD Million (2023-2028)
  • Table 229. India Arthritis Therapeutics, by Application USD Million (2023-2028)
  • Table 230. India Arthritis Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 231. India Arthritis Therapeutics, by Sales Channel USD Million (2023-2028)
  • Table 232. India Arthritis Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 233. India Arthritis Therapeutics, by Arthritis Type USD Million (2023-2028)
  • Table 234. South Korea Arthritis Therapeutics, by Application USD Million (2023-2028)
  • Table 235. South Korea Arthritis Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 236. South Korea Arthritis Therapeutics, by Sales Channel USD Million (2023-2028)
  • Table 237. South Korea Arthritis Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 238. South Korea Arthritis Therapeutics, by Arthritis Type USD Million (2023-2028)
  • Table 239. Taiwan Arthritis Therapeutics, by Application USD Million (2023-2028)
  • Table 240. Taiwan Arthritis Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 241. Taiwan Arthritis Therapeutics, by Sales Channel USD Million (2023-2028)
  • Table 242. Taiwan Arthritis Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 243. Taiwan Arthritis Therapeutics, by Arthritis Type USD Million (2023-2028)
  • Table 244. Australia Arthritis Therapeutics, by Application USD Million (2023-2028)
  • Table 245. Australia Arthritis Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 246. Australia Arthritis Therapeutics, by Sales Channel USD Million (2023-2028)
  • Table 247. Australia Arthritis Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 248. Australia Arthritis Therapeutics, by Arthritis Type USD Million (2023-2028)
  • Table 249. Rest of Asia-Pacific Arthritis Therapeutics, by Application USD Million (2023-2028)
  • Table 250. Rest of Asia-Pacific Arthritis Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 251. Rest of Asia-Pacific Arthritis Therapeutics, by Sales Channel USD Million (2023-2028)
  • Table 252. Rest of Asia-Pacific Arthritis Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 253. Rest of Asia-Pacific Arthritis Therapeutics, by Arthritis Type USD Million (2023-2028)
  • Table 254. Europe Arthritis Therapeutics, by Country USD Million (2023-2028)
  • Table 255. Europe Arthritis Therapeutics, by Application USD Million (2023-2028)
  • Table 256. Europe Arthritis Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 257. Europe Arthritis Therapeutics, by Sales Channel USD Million (2023-2028)
  • Table 258. Europe Arthritis Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 259. Europe Arthritis Therapeutics, by Arthritis Type USD Million (2023-2028)
  • Table 260. Germany Arthritis Therapeutics, by Application USD Million (2023-2028)
  • Table 261. Germany Arthritis Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 262. Germany Arthritis Therapeutics, by Sales Channel USD Million (2023-2028)
  • Table 263. Germany Arthritis Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 264. Germany Arthritis Therapeutics, by Arthritis Type USD Million (2023-2028)
  • Table 265. France Arthritis Therapeutics, by Application USD Million (2023-2028)
  • Table 266. France Arthritis Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 267. France Arthritis Therapeutics, by Sales Channel USD Million (2023-2028)
  • Table 268. France Arthritis Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 269. France Arthritis Therapeutics, by Arthritis Type USD Million (2023-2028)
  • Table 270. Italy Arthritis Therapeutics, by Application USD Million (2023-2028)
  • Table 271. Italy Arthritis Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 272. Italy Arthritis Therapeutics, by Sales Channel USD Million (2023-2028)
  • Table 273. Italy Arthritis Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 274. Italy Arthritis Therapeutics, by Arthritis Type USD Million (2023-2028)
  • Table 275. United Kingdom Arthritis Therapeutics, by Application USD Million (2023-2028)
  • Table 276. United Kingdom Arthritis Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 277. United Kingdom Arthritis Therapeutics, by Sales Channel USD Million (2023-2028)
  • Table 278. United Kingdom Arthritis Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 279. United Kingdom Arthritis Therapeutics, by Arthritis Type USD Million (2023-2028)
  • Table 280. Netherlands Arthritis Therapeutics, by Application USD Million (2023-2028)
  • Table 281. Netherlands Arthritis Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 282. Netherlands Arthritis Therapeutics, by Sales Channel USD Million (2023-2028)
  • Table 283. Netherlands Arthritis Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 284. Netherlands Arthritis Therapeutics, by Arthritis Type USD Million (2023-2028)
  • Table 285. Rest of Europe Arthritis Therapeutics, by Application USD Million (2023-2028)
  • Table 286. Rest of Europe Arthritis Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 287. Rest of Europe Arthritis Therapeutics, by Sales Channel USD Million (2023-2028)
  • Table 288. Rest of Europe Arthritis Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 289. Rest of Europe Arthritis Therapeutics, by Arthritis Type USD Million (2023-2028)
  • Table 290. MEA Arthritis Therapeutics, by Country USD Million (2023-2028)
  • Table 291. MEA Arthritis Therapeutics, by Application USD Million (2023-2028)
  • Table 292. MEA Arthritis Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 293. MEA Arthritis Therapeutics, by Sales Channel USD Million (2023-2028)
  • Table 294. MEA Arthritis Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 295. MEA Arthritis Therapeutics, by Arthritis Type USD Million (2023-2028)
  • Table 296. Middle East Arthritis Therapeutics, by Application USD Million (2023-2028)
  • Table 297. Middle East Arthritis Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 298. Middle East Arthritis Therapeutics, by Sales Channel USD Million (2023-2028)
  • Table 299. Middle East Arthritis Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 300. Middle East Arthritis Therapeutics, by Arthritis Type USD Million (2023-2028)
  • Table 301. Africa Arthritis Therapeutics, by Application USD Million (2023-2028)
  • Table 302. Africa Arthritis Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 303. Africa Arthritis Therapeutics, by Sales Channel USD Million (2023-2028)
  • Table 304. Africa Arthritis Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 305. Africa Arthritis Therapeutics, by Arthritis Type USD Million (2023-2028)
  • Table 306. North America Arthritis Therapeutics, by Country USD Million (2023-2028)
  • Table 307. North America Arthritis Therapeutics, by Application USD Million (2023-2028)
  • Table 308. North America Arthritis Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 309. North America Arthritis Therapeutics, by Sales Channel USD Million (2023-2028)
  • Table 310. North America Arthritis Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 311. North America Arthritis Therapeutics, by Arthritis Type USD Million (2023-2028)
  • Table 312. United States Arthritis Therapeutics, by Application USD Million (2023-2028)
  • Table 313. United States Arthritis Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 314. United States Arthritis Therapeutics, by Sales Channel USD Million (2023-2028)
  • Table 315. United States Arthritis Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 316. United States Arthritis Therapeutics, by Arthritis Type USD Million (2023-2028)
  • Table 317. Canada Arthritis Therapeutics, by Application USD Million (2023-2028)
  • Table 318. Canada Arthritis Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 319. Canada Arthritis Therapeutics, by Sales Channel USD Million (2023-2028)
  • Table 320. Canada Arthritis Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 321. Canada Arthritis Therapeutics, by Arthritis Type USD Million (2023-2028)
  • Table 322. Mexico Arthritis Therapeutics, by Application USD Million (2023-2028)
  • Table 323. Mexico Arthritis Therapeutics, by Route of Administration USD Million (2023-2028)
  • Table 324. Mexico Arthritis Therapeutics, by Sales Channel USD Million (2023-2028)
  • Table 325. Mexico Arthritis Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 326. Mexico Arthritis Therapeutics, by Arthritis Type USD Million (2023-2028)
  • Table 327. Research Programs/Design for This Report
  • Table 328. Key Data Information from Secondary Sources
  • Table 329. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Arthritis Therapeutics: by Application USD Million (2017-2022)
  • Figure 5. Global Arthritis Therapeutics: by Route of Administration USD Million (2017-2022)
  • Figure 6. Global Arthritis Therapeutics: by Sales Channel USD Million (2017-2022)
  • Figure 7. Global Arthritis Therapeutics: by Drug Class USD Million (2017-2022)
  • Figure 8. Global Arthritis Therapeutics: by Arthritis Type USD Million (2017-2022)
  • Figure 9. South America Arthritis Therapeutics Share (%), by Country
  • Figure 10. Asia Pacific Arthritis Therapeutics Share (%), by Country
  • Figure 11. Europe Arthritis Therapeutics Share (%), by Country
  • Figure 12. MEA Arthritis Therapeutics Share (%), by Country
  • Figure 13. North America Arthritis Therapeutics Share (%), by Country
  • Figure 14. Global Arthritis Therapeutics share by Players 2022 (%)
  • Figure 15. Global Arthritis Therapeutics share by Players (Top 3) 2022(%)
  • Figure 16. Global Arthritis Therapeutics share by Players (Top 5) 2022(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. Novartis AG (Switzerland) Revenue: by Geography 2022
  • Figure 20. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 21. Eli Lilly and Company (United States) Revenue: by Geography 2022
  • Figure 22. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Amgen Inc. (United States) Revenue: by Geography 2022
  • Figure 24. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Merck & Co., Inc. (United States) Revenue: by Geography 2022
  • Figure 26. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 27. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2022
  • Figure 28. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 30. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 31. Johnson & Johnson (United States) Revenue: by Geography 2022
  • Figure 32. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2022
  • Figure 34. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 35. Bayer AG (Germany) Revenue: by Geography 2022
  • Figure 36. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 37. Sanofi S.A. (France) Revenue: by Geography 2022
  • Figure 38. Global Arthritis Therapeutics: by Application USD Million (2023-2028)
  • Figure 39. Global Arthritis Therapeutics: by Route of Administration USD Million (2023-2028)
  • Figure 40. Global Arthritis Therapeutics: by Sales Channel USD Million (2023-2028)
  • Figure 41. Global Arthritis Therapeutics: by Drug Class USD Million (2023-2028)
  • Figure 42. Global Arthritis Therapeutics: by Arthritis Type USD Million (2023-2028)
  • Figure 43. South America Arthritis Therapeutics Share (%), by Country
  • Figure 44. Asia Pacific Arthritis Therapeutics Share (%), by Country
  • Figure 45. Europe Arthritis Therapeutics Share (%), by Country
  • Figure 46. MEA Arthritis Therapeutics Share (%), by Country
  • Figure 47. North America Arthritis Therapeutics Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Novartis AG (Switzerland)
  • Eli Lilly and Company (United States)
  • Amgen Inc. (United States)
  • Merck & Co., Inc. (United States)
  • Bristol-Myers Squibb Company (United States)
  • Pfizer Inc. (United States)
  • Johnson & Johnson (United States)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Bayer AG (Germany)
  • Sanofi S.A. (France)
Select User Access Type

Key Highlights of Report


May 2023 203 Pages 92 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Arthritis Therapeutics Market Quantitative research analysis
Global Arthritis Therapeutics Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Arthritis Therapeutics Market is heading robustly to achieve a new growth cycle.
The Concentration Rate of Global Arthritis Therapeutics market is dominated by United States and European Players and may generate healthy valuation by 2028.
  • Increasing prevalence in geriatric population especially women
  • Growing Use of Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
dominated the Arthritis Therapeutics market. This is attributable to growing trend of "Self-Awareness And Pro-Activeness To Seek Treatment"

Know More About Global Arthritis Therapeutics Market Report?

Have a Query? Click Here

Other Related Reports

Autoimmune Hepatitis Treatment Comprehensive Study by Disease Type (Type 1 autoimmune hepatitis, Type 2 autoimmune hepatitis), Treatment (Immunosuppressant Drugs (Corticosteroids), Liver Transplant),...
$ 3750
Diabetic Foot Ulcer Treatment Comprehensive Study by Type (Wound Care Dressings (Alginate Dressings, Hydrofiber Dressings, Foam Dressings, Film Dressing, Hydrocolloid Dressings, Surgical Dressings, H...
$ 3750
Polycystic Ovarian Syndrome Treatment Comprehensive Study by Treatment (Drug Class (Insulin Sensitizing Agent, Oral Contraceptive, Antiandrogens, Anti-Obesity Drugs and Others), Surgery (Ovarian Wedg...
$ 3750
Androgenetic Alopecia Treatment Comprehensive Study by Type (Drugs (Minoxidil, Dutasteride, Finasteride and Others), Low-level Laser Therapy, Microneedling and Hair Transplantation, Others), Distribu...
$ 3650
Tumor Lysis Syndrome Comprehensive Study by Treatment (Medications (allopurinol, rasburicase, sodium bicarbonate or acetazolamide, oral kinase inhibitors and B-cell lymphoma-2 protein inhibitors), Ki...
$ 3650
Insomnia Therapeutics Comprehensive Study by Type (Pharmacological Treatments (Prescription Sleep Aids, Over-the-Counter Sleep Aids), Non-pharmacological Treatments), Application (Clinics, Hospitals)...
$ 3450